Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

(2010) Gilda da Cunha Santos et al.   CANCER

ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma

(2010) J. Spencer Liles et al.   CANCER BIOLOGY & THERAPY

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

(2010) J. P. Arnoletti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

(2010) B. Schoeberl et al.   CANCER RESEARCH

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

(2010) Fumin Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities

(2009) Helmout Modjtahedi et al.   ANTI-CANCER DRUGS

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2009) I. J. Dahabreh et al.   CLINICAL CANCER RESEARCH

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2009) Bart Jacobs et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment

(2009) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis

(2009) B. Schoeberl et al.   Science Signaling

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression

(2008) R. F. Hwang et al.   CANCER RESEARCH

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Pancreatic stellate cells—role in pancreas cancer

(2008) Max G. Bachem et al.   LANGENBECKS ARCHIVES OF SURGERY